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BACKGROUND: Medical induction of ovulation using clomiphene citrate (CC) as ®rst line and exogenous gonado-
trophins as second line forms the classical treatment algorithm in normogonadotrophic anovulatory infertility.
Because the chances of success following classical ovulation induction are not well established, a shift in ®rst-line
therapy can be observed towards alternative treatment. The study aim was to: (i) reliably assess the probability of
singleton live birth following classical induction of ovulation; and (ii) construct a prediction model, based on individ-
ual patient characteristics assessed upon standardized initial screening, to help identify patients with poor chances
of success. METHODS: A total of 240 consecutive women visiting a specialist academic fertility unit with a history
of infertility, oligomenorrhoea or amenorrhoea, and normal FSH and estradiol serum concentrations (WHO group
2) was prospectively followed. The women had not been previously treated with ovulation-inducing agents. All
patients commenced with CC. Patients who did not ovulate within three treatment cycles of incremental daily doses
up to 150 mg for 5 consecutive days or ovulatory CC patients who did not conceive within six cycles, subsequently
underwent gonadotrophin induction of ovulation applying a step-down dose regimen. The main outcome measure
was pregnancy resulting in singleton live birth. Cox regression was used to construct a multivariable prediction
model. RESULTS: Overall, there were 134 pregnancies ending in a singleton live birth (56% of women). The cumu-
lative pregnancy rate after 12 and 24 months of follow-up was 50% and 71% respectively. Polycystic ovary syn-
drome (PCOS) patients (49%), clearly non-PCOS patients (13%) and the in-between group did not differ in
prognosis (P = 0.9). The multivariable Cox regression model contained the woman's age, the insulin:glucose ratio
and duration of infertility. With a cut-off value of 30% for low chance, the model predicted probabilities at 12
months lower than this cut-off for 25 out of 240 patients (10.4%). CONCLUSIONS: Classical ovulation induction
produces very good results in normogonadotrophic anovulatory infertility. Alternative treatment options may not
be indicated as ®rst-line therapy in these patients, except for subgroups with poor prognosis. These women can be
identi®ed by older age, longer duration of infertility and higher insulin:glucose ratio.
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Introduction
Anovulation is a common cause of infertility, and is diagnosed
in at least 25% of couples with fertility problems. In the great
majority of these women the underlying cause is described as
`pituitary-ovarian disbalance', where serum FSH and estradiol
(E2) levels are within normal limits [also described as World
Health Organization (WHO) group 2] (World Health
Organization, 1993; The ESHRE Capri Workshop Group,
1995). Patients suffering from polycystic ovary syndrome
(PCOS) are considered a subgroup of WHO 2 (Laven et al.,
2002). Since the early 1960s, patients have been treated
effectively with the anti-estrogen clomiphene citrate (CC), as
well as exogenous gonadotrophins. CC is generally applied as
®rst-line treatment in these women, due to low costs and minor
chances of side effects or complications. Traditionally,
exogenous gonadotrophins (especially FSH) are considered
second-line therapy in case of failure to ovulate or conceive
following CC. This treatment modality requires frequent
monitoring due to inherent risks of multiple follicle develop-
ment resulting in increased chances for ovarian hyperstimula-
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tion syndrome (OHSS) and multiple gestation, especially in
PCOS patients (Messinis and Milingos, 1997; Legro, 1998).
Over the years, numerous (mainly retrospective) studies have
established the overall effectiveness of either CC (Hammond
et al., 1983; Kousta et al., 1997) or FSH (White et al., 1996;
Fauser and Van Heusden, 1997; van Santbrink and Fauser,
1997) in varying groups of patients. However, data concerning
a prospective follow-up of a coherent CC and FSH treatment
strategy in a well-de®ned group of patients are not yet
available.
Over the past 10 years, increased attention has focused
towards alternative treatment options such as the insulin-
sensitizing agents (Glueck et al., 2002; Heard et al., 2002;
Nestler et al., 2002), aromatase inhibitors (Mitwally and
Casper, 2001), laparoscopic surgery of the ovaries (Cohen,
1996; Farquhar et al., 2001) or assisted reproduction such as
intrauterine insemination (IUI) or IVF (Buyalos and Lee, 1996;
Child et al., 2001). Most promising results of up to 80%
pregnancies have been reported by individual studies, but the
majority of these reports involved a limited number of selected
patients and were retrospective and uncontrolled. It is often
suggested that the multiple birth rate is reduced in comparison
with ovulation induction, but reliable information on multiple
births is mostly lacking.
There seems to be a clear need to ®rmly establish the success
and complication rates of the conventional approach for
ovulation induction (involving CC and FSH) in a large
unselected cohort of patients. The present report contains an
integrated analysis of chances for pregnancies resulting in
singleton live childbirth, extending previously reported out-
comes separately for CC (Imani et al., 2002a) and FSH (Imani
et al., 2002b; Mulders et al., 2003). In addition, a prediction
model is presented to help identify patients with poor chances
of success. This information may serve as point of reference for




Between November 1992 and May 1999, a consecutive series of 240
women attending the authors' infertility unit were included in the
present study using the following inclusion criteria: (i) oligomenor-
rhoea (bleeding intervals between 35 days and 6 months) or
amenorrhoea (bleeding interval >6 months); (ii) normal serum FSH
(1±10 IU/l) and E2 (150±400 pmol/l) levels (van Santbrink et al.,
1997); (iii) normal serum prolactin and thyroid-stimulating hormone
levels; (iv) spontaneous menses or positive bleeding response to
progestagen withdrawal; (v) a body mass index (BMI: body weight
divided by the square of the patient's height) >18 kg/m2; (vi) age
between 19 and 40 years; (vii) no previous use of ovulation-induction
agents; (viii) a total motile sperm count [TMC = ejaculate volume (ml)
3 sperm concentration (106/ml) 3 percentage of progressive motile
sperm) of the partner >13106; (ix) a negative history of or screening
for any tubal pathology; and (x) no indication for IUI. Institutional
review board approval was obtained from the human subjects
committee of the Erasmus Medical Center, and informed consent
was obtained from all study participants.
The standardized initial clinical, sonographic and endocrine
screening took place prior to the initiation of CC ovulation induction,
as has been described previously (Imani et al., 2002a). The clinical
screening included patient's age, type of infertility (primary or
secondary), cycle history (amenorrhoea or oligomenorrhoea), BMI,
waist-to-hip ratio (WHR) and previous medication and/or surgery.
Transvaginal sonography included assessment of ovarian volume
(ml), and total number of follicles, as described previously (Pache
et al., 1992). Endocrine screening included serum assays for FSH, LH,
E2, androstenedione, testosterone, sex-hormone binding globulin
(SHBG), and fasting insulin and glucose. The hormone assays used,
and the intra- and inter-assay coef®cients of variation valid for this
study, have all been described previously (Imani et al., 2000).
The treatment protocol and assessment of ovarian response and
pregnancy after CC administration have also been described
previously (Imani et al., 2002a). In brief, the women received initial
CC doses of 50 mg/day from cycle day 3 until day 7 after spontaneous
or progestagen-induced withdrawal bleeding. In cases of absent
ovarian response, the daily dosage was increased to 100 and 150 mg in
subsequent cycles. Ovulation after CC or FSH medication was
assessed by sonographic monitoring of disappearance of the pre-
ovulatory follicle and/or the ®nding of midluteal progesterone levels
>25 nmol/l. In case of CC-resistant anovulation (CRA)Ðthat is,
absent ovulation after 3 months, despite stimulation with a maximum
daily CC dose of 150 mgÐor if pregnancy failed to occur within six
ovulatory cycles, ovulation induction with exogenous recombinant
FSH (Puregonâ; Organon NV, Oss, The Netherlands) was applied as
second-line treatment, using a decremental dose regimen as published
previously (van Santbrink and Fauser, 1997). The FSH response dose
was assessed during the ®rst cycle applying a low-dose, step-up
regimen (Imani et al., 2002b; Mulders et al., 2003).
Pregnancy was de®ned as a positive urinary pregnancy test
(Clearview, hCG II; Unipath Ltd, Bedford, UK) at least 3 days after
the expected menses. Ongoing pregnancy was de®ned as sonographic
assessment at 12 weeks amenorrhoea of an intrauterine gestational sac
with a positive heartbeat. Live birth was de®ned as the delivery of a
baby after at least 28 weeks gestational age. Information regarding
deliveries and the health condition of the babies born was collected
using hospital records. In cases of home delivery, the information was
collected directly from the patient and her general practitioner or
midwife.
Statistical analysis
The Kaplan±Meier method was used to estimate the cumulative
pregnancy rate leading to singleton live birth. The period from the start
of CC treatment until the ®rst pregnancy leading to live birth was the
time variable in this analysis. Conceptions that ended in miscarriage
were ignored by the analysis, and in these cases follow-up continued
until pregnancy resulting in singleton live birth occurred. Patients who
had a pregnancy ending in premature birth, stillbirth or multiple live
birth, were considered censored at conception. Patients who did not
become pregnant were censored at their time of last treatment.
Spontaneous pregnancies resulting in singleton live birth that occurred
during the ®rst or second month after the end of treatment were also
included in the analysis.
Cox regression was used for univariable and multivariable analysis
relating initial screening characteristics to the cumulative pregnancy
rate leading to singleton live birth. In univariable analysis the log-rank
test was used, and a P-value < 0.05 was considered to be statistically
signi®cant. A multivariable prediction model was constructed using a
backward stepwise elimination method with P < 0.15 for exclusion of
predictors, corresponding to Akaike's Information Criterion (Akaike,
1973). Predictor variables with univariable P < 0.5 were candidate
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variables for the multivariable model. These `liberal' P-values were
chosen because the resulting model may be expected to have a better
predictive performance in new patients than when the strict P < 0.05
criterion is used (Harrell et al., 1996). The prediction model was
corrected by a shrinkage factor, determined by a bootstrapping
technique with 200 replications, to provide better predictions in new
patients (Van Houwelingen and Le Cessie, 1990; Harrell et al., 1996).
The discriminative ability of the prediction model was assessed by the
c-statistic, which is similar to the area under the receiver operating
characteristic (ROC) curve for dichotomous outcomes, and can range
from 0.5 to 1.0 (Harrell et al., 1985). The bootstrap technique was used
again, this time to correct the optimism in the apparent c-statistic
(Harrell et al., 1996). Missing values occurred for some screening
characteristics. The technique of multiple imputation was used to
avoid loss of information due to missing data in multivariable analyses
(Little, 1992). Missing data occurred in the WHR (45% missing),
semen analysis (25% missing) and insulin:glucose ratio (26%
missing). Statistical analyses were performed with SPSS for
Windows (version 10) and S+ 2000.
Results
Following the induction of ovulation, 162 pregnancies
occurred in 159 patients (66%). In total, 147 (90%) of the
pregnancies were ongoing (positive heart action upon ultra-
sound at 12 weeks amenorrhoea), whereas 15 miscarried within
12 weeks. Of the 147 ongoing pregnancies, 137 were singleton
and 10 were multiple (7% of ongoing pregnancies). Of the
singleton ongoing pregnancies, two ended in premature birth
and one in stillbirth. All other ongoing pregnancies ended in
live birth (134 singleton, 10 multiple). The cumulative
pregnancy rate resulting in singleton live birth is shown in
Figure 1. After 6, 12, 18 and 24 months of follow-up,
respectively 32, 50, 63 and 71% of patients presented with a
singleton pregnancy resulting in the live birth of a baby. The
cumulative chance after 24 months increased to 74% in case
multiple live births were included, and to 76% for all ongoing
pregnancies. The median time taken to reach pregnancy
resulting in singleton live birth was 11.7 months. The median
follow-up of the women who did not reach this end-point was
10 months, with a maximum follow-up of 4 years. Their
median duration of CC-treatment was 5.9 (range: 1±18)
months, during which time a median of 5.0 (range: 1±13)
CC-cycles were performed. The median duration of FSH
treatment of the women who did not reach the end-point was
7.0 (range: 1±34) months, with a median number of 5.0 (range:
1±13) FSH treatment cycles.
The fate of the women participating in the study is shown
diagrammatically in Figure 2. All 240 women started with CC,
and 57 (24%) of them were found to be CRA. CC outcome in
the remaining 183 women was 112 pregnancies: 98 ongoing
singleton and four ongoing twin pregnancies (4% of CC-
pregnancies) resulting in live birth, 11 pregnancies ending in
miscarriage (10% of CC-pregnancies) and one ending in
stillbirth. There was one additional miscarriage, in a woman
who became pregnant again after a ®rst miscarriage. There
were 84 women who started FSH induction of ovulation after
unsuccessful CC-treatment. In 44 women an ongoing preg-
nancy was subsequently achieved, and this resulted in 36
singleton, four twin, one triplet and one quadruplet live birth
(14% multiple births) and two stillbirths. There were three
pregnancies that miscarried (6% of 47 pregnancies). The
miscarriage rate was not statistically signi®cant between CC
and FSH (P = 0.7). Almost 50% (33 out of 71) of the CCF
patients did not proceed to FSH treatment and should be
considered as drop-outs. They did not differ from the patients
who started FSH treatment in any of the screening character-
istics, except for the level of endogenous FSH: the mean (6
SD) level was 4.1 6 1.7 versus 5.1 6 1.6 IU/l in the group that
started FSH treatment (P = 0.01).
The primary screening characteristics are detailed in Table I
for women who did and those who did not have a pregnancy
that led to a singleton live birth. Successful patients were
younger, infertile for a shorter period of time, thinner, had
marginally higher FSH, higher LH and lower insulin:glucose
ratios. The ®nal column indicates the screening characteristics
that had an independent contribution to the multivariable
prediction model: age, insulin:glucose ratio and duration of
infertility. The distribution of the predicted probabilities
calculated by this model (after shrinkage) for the 240 patients
in this study is shown in Figure 3. The individual predicted
probabilities ranged from 15 to 82%. When a predicted
probability at 12 months below 30% was considered as a poor
prognosis, the model was able to identify 25 out of 240 (10.4%)
as poor-prognosis patients.
In an additional analysis, WHO 2 patients were de®ned as
de®nitive PCOS in case they presented with an elevated free
androgen index (FAI) and polycystic ovaries (Laven et al.,
2002) (49% of the 240 patients; in accordance with a recent
PCOS consensus meeting), and clearly non-PCOS when the
FAI was normal and no signs of polycystic ovaries were
present (13% of patients). The remaining women (38% of
patients) formed the in-between group of possible PCOS.
Kaplan±Meier analysis for pregnancy leading to singleton live
birth showed no difference between these groups (P = 0.9).
Figure 1. Cumulative pregnancy rate resulting in singleton live
birth of a consecutive series of 240 normogonadotrophic
anovulatory infertile women undergoing classical ovulation
induction (CC as ®rst-line, followed by FSH as second-line therapy
if required), calculated by the Kaplan±Meier method, with 95%
con®dence interval.
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Discussion
The current prospective study demonstrated a cumulative
chance of pregnancy resulting in singleton live birth of 71%
within 2 years of classical ovulation induction (CC medication
followed by exogenous FSH as second-line therapy) in a well-
de®ned group of normogonadotrophic anovulatory infertile
women (WHO group 2). The chance increased to 74% in case
multiple live births were included, and to 76% for all ongoing
pregnancies. Of all live births, only 7% were multiple. These
®gures compared favourably with the outcome of alternative,
more complex treatment algorithms (Child et al., 2001; Heard
et al., 2002). Again, many studies involving alternative
therapies are retrospective, and involve a small and selected
group of patients. Moreover, singleton live birth is rarely used
as an end-point. The above-mentioned observations are in
favour of the contention that classical ovulation induction
should remain the ®rst-line treatment of choice in these
women.
A prognostic model based on age of the woman, the
insulin:glucose ratio and the duration of infertility predicted
probabilities of pregnancy resulting in singleton live birth at 12
months ranging from 15 to 82%. The apparent c-statistic of the
model was 0.64, and the optimism-corrected value was 0.61,
indicating only a moderate discriminative ability. However, the
model was able to identify patients with low chances for
success applying classical ovulation induction who may
therefore qualify for alternative ®rst-line treatment options
such as insulin-sensitizing agents, assisted reproductive tech-
nologies or laparoscopic ovarian surgery. For example, a
probability lower than 30% was predicted in 25 (10%) out of
the 240 patients. However, this cut-off value for low chance of
30% was arbitrarily chosen and other values may be just as
valid. In a general infertility setting, the individual choice
between several treatment options should depend on the
chances of success, the complication rates, the burden to the
patient, and costs. Taking these considerations into account,
clinicians can choose any desired cut-off value for the chance
of success of ovulation induction, and derive from Figure 3
how many patients will be identi®ed as having a low chance of
success. In previous studies by the present authors, with regard
to outcome following CC-treatment alone, a history of
amenorrhoea (as opposed to oligomenorrhoea) was found to
be an adverse factor for ovulation (Imani et al., 1998), but a
positive factor for pregnancy once ovulation was achieved
(Imani et al., 1999). In the present study, amenorrhoea had no
effect on outcome, indicating that probably both effects level
out, as had been noted previously (Imani et al., 2002a).
Additional factors involved in the prediction of live birth
following CC treatment included FAI, BMI and female age.
Previously identi®ed screening characteristics involved in the
prediction of ongoing pregnancy following FSH ovulation
induction included concentrations of both insulin-like growth
factor-1 (IGF-I) and testosterone, as well as age (Mulders et al.,
2003).
Almost 50% of the CC-failure (CCF) patients did not
proceed to FSH treatment and should be considered as drop-
outs. In general, drop-outs may cause bias in the estimates of
outcome when their prognosis differs from the patients who did
not drop out (`selective drop-out'), as noted in a previous study
(Imani et al., 2002a). However, the screening characteristics
that were predictive of success were similar between these
patients and the patients who continued with FSH treatment.
Only endogenous FSH levels were different, but since that
screening characteristic was not associated with outcome in the
prognostic model, it can be concluded that there is no
Figure 2. Outcomes during classical induction of ovulation in 240
normogonadotrophic anovulatory infertile women. *Drop-out after
CC occurred in 44 patients. In 13 cases because the couple no
longer had an active child wish, in seven cases because further
treatment was found too burdensome, in nine cases because of
medical problems, and in 15 cases because another therapy was
started (IVF or IUI). **Two women with miscarriages following CC
presented with an ongoing pregnancy after a subsequent second
(one patient) or third (one patient) pregnancy with CC. ***FSH
treatment was discontinued by 37 patients without their becoming
pregnant. In three cases this was because the couple no longer had
an active wish for a child, in one case because treatment was found
too burdensome, in six cases because of medical problems, and in
22 cases because the couples started another therapy (IVF). Five
couples had not yet planned another treatment at the end of follow-
up. ****Multiple ongoing pregnancies with CC occurred four times,
all of which were twins. With FSH, six multiple live birth occurred
(four twins, one triplet, one quadruplet). CCF = CC failure (absence




indication of selective drop-out. The 37 women who did not
reach the end-point following FSH treatment had received a
median number of ®ve treatment cycles, which was close to the
standard number of treatment cycles according to protocol.
Therefore they were not to be considered as drop-outs.
It is generally perceived that the majority of patients who
qualify for exogenous gonadotrophins for ovulation induction
suffer from PCOS (White et al., 1996; Fauser and Van
Heusden, 1997). However, scienti®c evidence to support this
believe is scant. It has recently been established that 70% of
women suffering from normogonadotrophic anovulation pre-
sent with polycystic ovaries as diagnosed by ultrasound, and
61% with endocrine signs associated with PCOS (i.e.
hyperandrogenaemia) (Laven et al., 2002). However, insulin
resistanceÐas de®ned by an increased fasting insulin:glucose
ratioÐwas observed in only 21% of women, whereas 44%
were obese. All these clinical, endocrine and ultrasound
abnormalities are involved in ovarian dysfunction in PCOS,
and may therefore potentially predict response and outcome of
ovarian stimulation by exogenous FSH (Balen et al., 1993;
Fulghesu et al., 1997). It was surprising therefore to ®nd that
none of these featuresÐexcept for insulin resistanceÐcould be
identi®ed in the present study as a predictor of pregnancy in
multivariable analysis. Moreover, in case the overall hetero-
geneous WHO 2 group was classi®ed according to de®nitive
PCOS or de®nitive non-PCOS (see Results section for details),
again no differences in pregnancy chances could be observed.
Not even obesity (de®ned as an elevated BMI) or abnormal fat
distribution (indicated by a high WHR) was capable of
predicting outcome, despite much emphasis in recent literature
on the impact of excess bodyweight (Hamilton-Fairley et al.,
1992) and weight reduction (Norman et al., 2002) on the
success of fertility therapies in anovulatory women. These
discrepancies clearly underline the need for properly designed,
prospective studies in a well-de®ned patient population.
In conclusion, the results of the present study showed that,
overall, normogonadotrophic anovulatory women have good
prospects of singleton live birth when treated according to the
classical induction of ovulation algorithm, including CC as
®rst-line treatment followed by exogenous FSH as second line.
Using a multivariate prediction model, individual women with
chances for success (far) above or below average can be
identi®ed. For women with a predicted low chance, the use of
alternative treatment strategies may be appropriate.
Table I. Clinical, endocrine and ultrasound screening characteristics (mean 6 SD) of 240 normogonadotrophic anovulatory infertile women before initiation
of classical ovulation induction (CC as ®rst-line; FSH as second-line therapy), and separately for those women who did or did not achieve pregnancy
resulting in singleton live birth
Screening parameter Overall group Pregnancy resulting in singleton live birth Multivariable
(n = 240) Hazard ratio
No (n = 106) Yes (n = 134) Pa (95% CI)b
Age (years) 27.8 6 4.3 28.7 6 4.5 27.1 6 4.0 <0.001 0.91 (0.87±0.95)
Duration of infertility (years) 2.1 6 2.1 2.5 6 2.5 1.9 6 1.6 0.02 0.91 (0.81±1.02)
% Primary infertility (n) 75% (181) 72% (76) 78% (105) 0.17 ±
% Oligomenorrhoea (n) 78% (187) 79% (84) 77% (103) 0.9 ±
BMI (kg/m2) 26.9 6 6.2 27.7 6 6.8 26.2 6 5.6 0.02 ±
WHR 0.84 6 0.10 0.85 6 0.09 0.83 6 0.10 0.28 ±
FAI (T 3 100/SHBG) 6.2 6 4.6 6.3 6 4.7 6.2 6 4.6 0.5 ±
FSH (IU/l) 4.7 6 1.5 4.4 6 1.4 4.8 6 1.5 0.07 ±
LH (IU/l) 7.6 6 4.3 7.2 6 4.0 7.9 6 4.6 0.04 ±
Estradiol (pmol/l) 240 6 136 249 6 139 233 6 133 0.20 ±
Insulin:glucose ratio 3.4 6 2.1 3.6 6 2.4 3.2 6 1.8 0.04 0.87 (0.79±0.96)
% Polycystic ovaries (n)c 74% (178) 75% (79) 74% (99) 0.8 ±
Total motile sperm countd 68 (1±693) 52 (1±662) 80 (1±693) 0.9 ±
aLog-Rank test.
bHazard ratios for pregnancy resulting in singleton live birth with 95% Con®dence Interval (CI) of the screening characteristics that were selected into the
multivariable model. The formula (after shrinkage) to calculate the 12 month predicted probability for a new patient is:
1 ± EXP{±8.3 3 EXP[±0.072 3 age (years) ± 0.107 3 (insulin:glucose ratio) ± 0.069 3 duration (years)]}.
In this formula, `EXP' denotes the standard exponential function, which must be applied twice.
cPolycystic ovaries de®ned as mean ovarian volume >10.8 ml and/or mean follicle number per ovary <10 (van Santbrink et al., 1997).
dValues are median (range).
BMI = body mass index; FAI = free androgen index; SHBG = sex hormone-binding globulin; T = testosterone; WHR = waist-to-hip ratio
Figure 3. Distribution of predicted probabilities of pregnancy at 12
months resulting in singleton live birth following classical induction
of ovulation in 240 normogonadotrophic anovulatory infertile
women. Predictions by the Cox regression model with age,
insulin:glucose ratio and duration of infertility.
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